Chung Jung Wha, Kim Gi Hyun, Lee Jong Ho, Ok Kyeong Sam, Jang Eun Sun, Jeong Sook-Hyang, Kim Jin-Wook
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Clin Mol Hepatol. 2014 Dec;20(4):384-91. doi: 10.3350/cmh.2014.20.4.384. Epub 2014 Dec 24.
BACKGROUND/AIMS: Portal-vein thrombosis (PVT) develops in 10-25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictors of response to anticoagulation therapy in cirrhotic patients.
Patients with liver cirrhosis and nonmalignant PVT were identified by a hospital electronic medical record system (called BESTCARE). Patients with malignant PVT, Budd-Chiari syndrome, underlying primary hematologic disorders, or preexisting extrahepatic thrombosis were excluded from the analysis. Patients were divided into two groups (treatment and nontreatment), and propensity score matching analysis was performed to identify control patients. The sizes of the thrombus and spleen were evaluated using multidetector computed tomography.
Twenty-eight patients were enrolled in this study between 2003 and 2014: 14 patients who received warfarin for nonmalignant PVT and 14 patients who received no anticoagulation. After 112 days of treatment, 11 patients exhibited significantly higher response rates (complete in 6 and partial in 5) compared to the control patients, with decreases in thrombus size of >30%. Compared to nonresponders, the 11 responders were older, and had a thinner spleen and fewer episodes of previous endoscopic variceal ligations, whereas pretreatment liver function and changes in prothrombin time after anticoagulation did not differ significantly between the two groups. Two patients died after warfarin therapy, but the causes of death were not related to anticoagulation.
Warfarin can be safely administered to cirrhotic patients with nonmalignant PVT. The presence of preexisting portal hypertension is a predictor of nonresponse to anticoagulation.
背景/目的:门静脉血栓形成(PVT)在10%-25%的肝硬化患者中出现,可能会加重门静脉高压。关于抗凝治疗对肝硬化非恶性PVT影响的数据较少。本研究的目的是阐明肝硬化患者抗凝治疗的安全性、疗效及反应预测因素。
通过医院电子病历系统(BESTCARE)识别肝硬化合并非恶性PVT患者。分析中排除了恶性PVT、布加综合征、潜在原发性血液系统疾病或既往存在肝外血栓形成的患者。将患者分为两组(治疗组和非治疗组),进行倾向评分匹配分析以确定对照患者。使用多排螺旋计算机断层扫描评估血栓和脾脏大小。
2003年至2014年期间本研究纳入28例患者:14例接受华法林治疗非恶性PVT,14例未接受抗凝治疗。治疗112天后,11例患者的反应率显著高于对照患者(6例完全缓解,5例部分缓解),血栓大小减少>30%。与无反应者相比,11例有反应者年龄较大,脾脏较薄,既往内镜下静脉曲张结扎次数较少,而两组之间治疗前肝功能及抗凝后凝血酶原时间变化无显著差异。两名患者在华法林治疗后死亡,但死亡原因与抗凝无关。
华法林可安全用于肝硬化合并非恶性PVT患者。既往存在门静脉高压是抗凝治疗无反应的预测因素。